News
12-16-2010, 05:11 AM
The National Institute for Health and Clinical Excellence (NICE) has opened a consultation on preliminary draft guidance about the use of lapatinib (Tyverb, GlaxoSmithKline) and trastuzumab (Herceptin, Roche Products) when either is used in combination with an aromatase inhibitor (another type of breast cancer treatment) for patients with a particular type of breast cancer...
More... (http://mnt.to/f/3P7V)
More... (http://mnt.to/f/3P7V)